$MCRB
Seres Therapeutics, Inc.

2020 Q1 Form 10-Q Financial Statement

#000156459020022457 Filed on May 07, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q1
Revenue $8.190M $6.615M
YoY Change 23.81% 66.58%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.140M $7.500M
YoY Change -18.13% -14.58%
% of Gross Profit
Research & Development $21.74M $22.89M
YoY Change -5.02% -2.43%
% of Gross Profit
Depreciation & Amortization $1.802M $2.006M
YoY Change -10.17% 3.35%
% of Gross Profit
Operating Expenses $27.88M $31.87M
YoY Change -12.53% -1.13%
Operating Profit -$19.69M -$24.55M
YoY Change -19.8% -13.14%
Interest Expense -$560.0K $220.0K
YoY Change -354.55% -36.6%
% of Operating Profit
Other Income/Expense, Net -$189.0K $220.0K
YoY Change -185.91% -36.6%
Pretax Income -$19.88M -$24.33M
YoY Change -18.29% -12.86%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$19.88M -$24.33M
YoY Change -18.3% -12.84%
Net Earnings / Revenue -242.75% -367.85%
Basic Earnings Per Share
Diluted Earnings Per Share -$280.7K -$593.0K
COMMON SHARES
Basic Shares Outstanding 71.07M 41.05M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q1 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $75.10M $53.71M
YoY Change 39.81% -56.04%
Cash & Equivalents $54.86M $53.71M
Short-Term Investments $20.20M $0.00
Other Short-Term Assets $3.400M $7.500M
YoY Change -54.67% 74.42%
Inventory
Prepaid Expenses
Receivables $2.100M $6.667M
Other Receivables $0.00 $0.00
Total Short-Term Assets $80.60M $67.80M
YoY Change 18.88% -46.4%
LONG-TERM ASSETS
Property, Plant & Equipment $28.70M $37.80M
YoY Change -24.07% 20.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.400M $1.500M
YoY Change -6.67% 0.0%
Total Long-Term Assets $30.00M $39.20M
YoY Change -23.47% 19.15%
TOTAL ASSETS
Total Short-Term Assets $80.60M $67.80M
Total Long-Term Assets $30.00M $39.20M
Total Assets $110.6M $107.0M
YoY Change 3.36% -32.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.500M $3.900M
YoY Change 41.03% -27.78%
Accrued Expenses $7.000M $8.000M
YoY Change -12.5% 300.0%
Deferred Revenue $2.770M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $44.10M $41.57M
YoY Change 6.09% 18.09%
LONG-TERM LIABILITIES
Long-Term Debt $24.80M $0.00
YoY Change
Other Long-Term Liabilities $103.4M $644.0K
YoY Change 15955.9% -99.44%
Total Long-Term Liabilities $128.2M $644.0K
YoY Change 19806.83% -99.44%
TOTAL LIABILITIES
Total Short-Term Liabilities $44.10M $41.57M
Total Long-Term Liabilities $128.2M $644.0K
Total Liabilities $172.3M $176.9M
YoY Change -2.59% 18.39%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock $343.9M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$61.65M -$69.83M
YoY Change
Total Liabilities & Shareholders Equity $110.6M $107.0M
YoY Change 3.36% -32.87%

Cashflow Statement

Concept 2020 Q1 2019 Q1
OPERATING ACTIVITIES
Net Income -$19.88M -$24.33M
YoY Change -18.3% -12.84%
Depreciation, Depletion And Amortization $1.802M $2.006M
YoY Change -10.17% 3.35%
Cash From Operating Activities -$24.25M -$32.39M
YoY Change -25.14% 21.04%
INVESTING ACTIVITIES
Capital Expenditures $71.00K $306.0K
YoY Change -76.8% -67.89%
Acquisitions
YoY Change
Other Investing Activities $9.500M $0.00
YoY Change -100.0%
Cash From Investing Activities $9.437M -$306.0K
YoY Change -3183.99% -100.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.545M 480.0K
YoY Change 846.88% -390.91%
NET CHANGE
Cash From Operating Activities -24.25M -32.39M
Cash From Investing Activities 9.437M -306.0K
Cash From Financing Activities 4.545M 480.0K
Net Change In Cash -10.27M -32.22M
YoY Change -68.13% -390.1%
FREE CASH FLOW
Cash From Operating Activities -$24.25M -$32.39M
Capital Expenditures $71.00K $306.0K
Free Cash Flow -$24.32M -$32.70M
YoY Change -25.62% 17.98%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
27881000
CY2020Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
159000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-19692000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-24553000
CY2019Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
220000
CY2020Q1 mcrb Non Cash Operating Lease Cost
NonCashOperatingLeaseCost
536000
CY2020Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
368000
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-189000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-19881000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.28
CY2019Q1 mcrb Non Cash Operating Lease Cost
NonCashOperatingLeaseCost
535000
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
70821514
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-10000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-10000
CY2020Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
66000
CY2020Q1 mcrb Noncash Interest Expense
NoncashInterestExpense
314000
CY2020Q1 mcrb Revenue From Research Agreement
RevenueFromResearchAgreement
1988000
CY2019Q1 us-gaap Restructuring Charges
RestructuringCharges
1492000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19891000
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24333000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-48045000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
120000
CY2019Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
153000
CY2019Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
207000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2065000
CY2020Q1 mcrb Stock Issued During Period Value At Market Equity Offerings
StockIssuedDuringPeriodValueAtMarketEquityOfferings
4178000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
60000
CY2020Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
120000
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
249000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1959000
CY2020Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-10000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1959000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2065000
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1802000
CY2019Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2006000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-203000
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
643000
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
237000
CY2019Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6667000
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-6634000
CY2019Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-208000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
590000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2474000
CY2020Q1 mcrb Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1066000
CY2019Q1 mcrb Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1024000
CY2020Q1 mcrb Increase Decrease In Accrued Expenses And Other Current And Long Term Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentAndLongTermLiabilities
-1771000
CY2019Q1 mcrb Increase Decrease In Accrued Expenses And Other Current And Long Term Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentAndLongTermLiabilities
-1650000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24251000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32393000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
71000
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
306000
CY2020Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
12931000
CY2020Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
22439000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
9437000
CY2020Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
716000
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
220000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-24333000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
41027824
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-32219000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-306000
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
60000
CY2019Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
120000
CY2020Q1 mcrb Proceeds From Issuance Of Common Stock And Restricted Common Stock
ProceedsFromIssuanceOfCommonStockAndRestrictedCommonStock
120000
CY2019Q1 mcrb Proceeds From Issuance Of Common Stock And Restricted Common Stock
ProceedsFromIssuanceOfCommonStockAndRestrictedCommonStock
153000
CY2020Q1 mcrb Proceeds From At The Market Equity Offering Net Of Commissions
ProceedsFromAtTheMarketEquityOfferingNetOfCommissions
4116000
CY2020Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
249000
CY2019Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
207000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4545000
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
480000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10269000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65126000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
85933000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54857000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53714000
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
610000
CY2020Q1 mcrb Unsettled Issuance Of Common Stock From At The Market Offering
UnsettledIssuanceOfCommonStockFromAtTheMarketOffering
62000
CY2020Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
133000
CY2019Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
134000
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition and the accrual of research and development expenses. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including revenue, operating expenses, clinical trials and employee-related amounts, will depend on future developments that are highly uncertain, including new information that may emerge concerning COVID-19 and the actions taken to contain it or treat its impact and the economic impact on local, regional, national and international markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results could differ from the Company&#8217;s estimates.</p>
CY2019Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2019Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9065743
CY2020Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2010-10-31
CY2020Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
75094000
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10790286
CY2020Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
20247000
CY2020Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
10000
CY2020Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
20237000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
29689000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
29690000
CY2020Q1 mcrb Cash Equivalents Original Maturity Maximum Period
CashEquivalentsOriginalMaturityMaximumPeriod
P90D
CY2020Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
47380000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
47237000
CY2020Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
29544000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
27742000
CY2020Q1 mcrb Accrued Development And Clinical Manufacturing Costs Current
AccruedDevelopmentAndClinicalManufacturingCostsCurrent
5974000
CY2019Q4 mcrb Accrued Development And Clinical Manufacturing Costs Current
AccruedDevelopmentAndClinicalManufacturingCostsCurrent
5605000
CY2020Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2333000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4609000
CY2020Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
834000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
670000
CY2019Q1 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.30
CY2020Q1 us-gaap Restructuring Charges
RestructuringCharges
0
CY2019Q1 us-gaap Payments For Restructuring
PaymentsForRestructuring
608000
CY2020Q1 us-gaap Payments For Restructuring
PaymentsForRestructuring
192000
CY2020Q1 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2020Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
949000
CY2020Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
11970000
CY2020Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
12081000
CY2020Q1 us-gaap Long Term Debt
LongTermDebt
25000000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8310683
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2957750
CY2020Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
110967
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
401873
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10755593
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
10755593
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5080248
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.36
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.30
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.48
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
8.62
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.58
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
8.58
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
12.41
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3D
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M17D
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y4M17D
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y4M17D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3427000
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4055000
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
4055000
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3110000
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.60
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1959000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2065000
CY2020Q1 mcrb Collaborative Arrangement Upfront License Fee Received
CollaborativeArrangementUpfrontLicenseFeeReceived
120000000
CY2020Q1 mcrb Contract With Customer Liability Revenue Recognized With Related Party
ContractWithCustomerLiabilityRevenueRecognizedWithRelatedParty
6634000
CY2019Q1 mcrb Contract With Customer Liability Revenue Recognized With Related Party
ContractWithCustomerLiabilityRevenueRecognizedWithRelatedParty
6615000
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q1 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2019Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0

Files In Submission

Name View Source Status
0001564590-20-022457-index-headers.html Edgar Link pending
0001564590-20-022457-index.html Edgar Link pending
0001564590-20-022457.txt Edgar Link pending
0001564590-20-022457-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mcrb-10q_20200331.htm Edgar Link pending
mcrb-20200331.xml Edgar Link completed
mcrb-20200331.xsd Edgar Link pending
mcrb-20200331_cal.xml Edgar Link unprocessable
mcrb-20200331_def.xml Edgar Link unprocessable
mcrb-20200331_lab.xml Edgar Link unprocessable
mcrb-20200331_pre.xml Edgar Link unprocessable
mcrb-ex101_102.htm Edgar Link pending
mcrb-ex102_103.htm Edgar Link pending
mcrb-ex311_10.htm Edgar Link pending
mcrb-ex312_8.htm Edgar Link pending
mcrb-ex321_6.htm Edgar Link pending
mcrb-ex322_11.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending